Electromed presented its financial performance and market potential at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company, led by CEO Jim Cunniff and CFO Brad Nagel, reported a trailing 12-month revenue of $73.78 million, reflecting a 15.3% growth rate. The company boasts a gross margin of roughly 78%, $20 million in cash, and no debt, with a market capitalization of $221 million. Analysts have set stock price targets ranging from $47 to $50, with a P/E ratio of 20.45 and a PEG ratio of 0.38. Electromed has completed a $10 million share repurchase program and has another $10 million authorization available.
The company's primary focus is on bronchiectasis, a condition affecting approximately 1 million Americans. Currently, only about 150,000 patients use airway clearance technology, leaving around 850,000 untreated or undiagnosed. About 35% of these patients are under pulmonologist care. The average selling price for Electromed's devices exceeds $10,500, with a total addressable market estimated at $3 billion from the untreated group alone.
Electromed's revenue is predominantly derived from the home care market, accounting for 94% of total revenue. The hospital business, a growing segment, accounts for the remaining 6%. International sales remain minimal, at about 1% of total revenue. Direct contracts cover 87% of the U.S. patient population through Medicare and commercial payers.
Patients typically use Electromed's devices twice a day for 15 minutes each time. Clinical outcomes show a 57% lower antibiotic use, a 59% lower hospitalization rate, and a 75% reduction in emergency room visits. The company's documentation system, SmartNote, tracks baseline assessments at delivery, follow-ups at 5 days, and final assessments at 30 days to share with prescribing pulmonologists.
Electromed employs about 200 people and is headquartered near Minneapolis. The company manufactures its products domestically in the United States. Its SmartVest uses high-frequency chest wall oscillation with a patented single-hose design and a lightweight vest. The device is also used to treat cystic fibrosis and neuromuscular diseases.
The industry is experiencing catalysts such as new 2026 treatment guidelines released by CHEST and the NTM Bronchiectasis Foundation. Additionally, the FDA approval of the first inflammation-targeting bronchiectasis drug has spurred significant disease awareness efforts.
